The US FDA has approved asundexian, introducing the first-in-the-world factor XIa inhibitor to reduce the risk of secondary stroke in adults with a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic...
The US FDA has approved asundexian, introducing the first-in-the-world factor XIa inhibitor to reduce the risk of secondary stroke in adults with a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic...
The US FDA has approved...